W.R. Grace & Co. will sell its chromatography product lines, which includes chromatography instruments, columns, and other related products.
W.R Grace & Co announced on May 23, 2016 that it will sell product lines associated with its chromatography instruments, columns, and related laboratory products businesses. The company said it plans to focus on its pharmaceutical and nutraceutical business. According to a press announcement, Grace will continue to supply Vydac and Davisil media for process chromatography, Syloid FP excipients for drug formulations, and custom manufacturing of regulatory starting materials and intermediates.
The company said that it will sell its flash chromatography and ELSD instrument business to BUCHI Corporation, a division of BUCHI Labortechnik AG, a Swiss manufacturer and supplier of laboratory equipment. The sale includes Reveleris purification systems, GraceResolv and Reveleris Flash Cartridges, and Alltech ELSD 3300 instrumentation.
Dr. Maisch GmBH, a German company focusing on high-performance liquid chromatography (HPLC), will purchase Grace’s line of analytical HPLC columns, preparative columns, and packing equipment and services. This includes Exsil, Modsil, and Exmere Media, the Alltech HPLC column brands Adsorbosphere, Allsphere, Brava, Econophere, Gracesmart, Platinum, and Visionht brands. Also included is the ModCol brand including Spring Preparative Column Hardware, Multipacker packing equipment ad packing services.
Hichrom Ltd. will acquire Grace’s Vydac column brand, in addition to the Alltima, Allsep, Apex, Apollo, Genesis, and Prevail HPLC column brands. The Grace and Alltech solid phase extraction cartridge brands Maxi-Clean, Extract-Clean, and Gracepure will be acquired by S*Pure Pte Ltd., a laboratory equipment supplier based in Singapore.
Source: Grace
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.